Consent Decree Tempers J&J Consumer Outlook Even As Remediation Ends
This article was originally published in The Rose Sheet
Executive Summary
Skin-care and OTC product sales helped propel J&J’s consumer business in the fiscal 2015 first quarter, but currency headwinds dragged on results. CFO Dominic Caruso says the firm is stocking shelves more consistently with previously recalled OTCs, but FDA still needs to sign off on J&J’s remediation work before it returns to full manufacturing capacity, and the agency will monitor the company for a further five years under a 2011 consent decree.